Skip to main content

Strong Stewart W's Form 4 filing

Haemonetics CorpHAE · filed Jun 9, 2023

Accession no.
0001127602-23-018423
Filed
Jun 9, 2023
Trade date
Jun 7, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $223.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Strong Stewart WCIK 0001420910Officer (President, Global Hospital)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 7, 2023Common StockMOption exerciseAcquired+4,483$56.57+$253,603.3121,630Direct
Jun 7, 2023Common StockMOption exerciseAcquired+2,410$57.60+$138,81624,040Direct
Jun 7, 2023Common StockFTax withholdingDisposed−5,053$88.00−$444,66418,987Direct
Jun 7, 2023Common StockSSaleDisposed−2,538$88.04F3−$223,445.5216,449Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 7, 2023Common StockMOption exerciseDisposed−4,483$0.00$04,483Direct
Jun 7, 2023Common StockMOption exerciseDisposed−2,410$0.00$07,231Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.12, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this report.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)